Endometrial Neoplasms Clinical Trial
Official title:
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS). As of Amendment 7 eligible participants on study completion will be able to transition to an extension study, if available, in which they can continue to receive pembrolizumab monotherapy, lenvatinib monotherapy, or a combination of both pembrolizumab and lenvatinib as received in the parent study.
This China extension study will include participants previously enrolled in China in the global study for MK-7902-001 (NCT03884101) plus those enrolled during the China extension enrollment period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT06409039 -
POLE-END REAL LIFE: Endometrial Cancer Early Stages I-II and Advanced Stages III and IV Evaluation of POLE as a Prognostic Factor. Participants Are Women >= 18 Years Old, With the Pole Mutation
|
||
| Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
| Completed |
NCT00377520 -
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
| Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05682950 -
Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05974995 -
Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer
|
N/A | |
| Recruiting |
NCT03291275 -
Survival Outcomes of Uterine Malignancies in Chinese Population
|
N/A | |
| Recruiting |
NCT03291106 -
Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
|
||
| Completed |
NCT00341458 -
Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
|
||
| Terminated |
NCT05067972 -
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05795244 -
Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)
|
Phase 2 | |
| Recruiting |
NCT05770102 -
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
|
Phase 2/Phase 3 | |
| Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
| Terminated |
NCT01969396 -
Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology
|
N/A | |
| Completed |
NCT01460979 -
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT05869123 -
Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Active, not recruiting |
NCT05588076 -
Endometrial Lesions Predictions
|
||
| Active, not recruiting |
NCT03935282 -
Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors
|
N/A |